China-based Nasal-Phyto Pharmaceutical Technology Group Co., Ltd has announced receiving clinical clearance from the US Food and Drug Administration (FDA) for its NPRD003, the world’s first precision olfactory area constant flow drip drug-device combination product. The product is indicated for the treatment of cerebral vasospasm secondary to subarachnoid hemorrhage (SAH).
NPRD003: A Revolutionary Approach to SAH Treatment
NPRD003 utilizes Nasal Phyto’s proprietary precision olfactory constant flow drip technology to deliver drugs directly into the brain via the “olfactory mucosal pathway”. This innovative method is designed to reduce the hypotensive side effects of the drug while enhancing the prognostic efficacy of SAH treatment, offering a new approach to managing this critical condition.
Nasal-Phyto Pharma: A Leader in Nano-Drug Nasal-Brain Delivery System
Founded in 2019, Nasal-Phyto Pharma is a pioneer in the nano-drug nasal-brain delivery system. The company boasts a suite of advanced technologies, including the precision olfactory area constant flow drip technology, olfactory area targeted spray technology, and a characteristic nasal brain delivery non-clinical evaluation system that spans from rodents to non-human primates. These technologies position Nasal-Phyto Pharma at the forefront of drug delivery innovation, particularly in the area of olfactory and brain-targeted therapies.-Fineline Info & Tech
